Home
>
National Drug Code (NDC)
>
Celontin
Celontin - 0071-0525-24 - (methsuximide)
Drug Information of Celontin
| Product NDC: | 0071-0525 |
| Proprietary Name: | Celontin |
| Non Proprietary Name: | methsuximide |
| Active Ingredient(s): | 300 mg/1 & nbsp; methsuximide |
| Administration Route(s): | ORAL |
| Dosage Form(s): | CAPSULE |
| Coding System: | National Drug Codes(NDC) |
Labeler Information of Celontin
| Product NDC: | 0071-0525 |
| Labeler Name: | Parke-Davis Div of Pfizer Inc |
| Product Type: | HUMAN PRESCRIPTION DRUG |
| FDA Application Number: | NDA010596 |
| Marketing Category: | NDA |
| Start Marketing Date: | 19570208 |
Package Information of Celontin
| Package NDC: | 0071-0525-24 |
| Package Description: | 100 CAPSULE in 1 BOTTLE (0071-0525-24) |
NDC Information of Celontin
| NDC Code | 0071-0525-24 |
| Proprietary Name | Celontin |
| Package Description | 100 CAPSULE in 1 BOTTLE (0071-0525-24) |
| Product NDC | 0071-0525 |
| Product Type Name | HUMAN PRESCRIPTION DRUG |
| Non Proprietary Name | methsuximide |
| Dosage Form Name | CAPSULE |
| Route Name | ORAL |
| Start Marketing Date | 19570208 |
| Marketing Category Name | NDA |
| Labeler Name | Parke-Davis Div of Pfizer Inc |
| Substance Name | METHSUXIMIDE |
| Strength Number | 300 |
| Strength Unit | mg/1 |
| Pharmaceutical Classes | Anti-epileptic Agent [EPC],Decreased Central Nervous System Disorganized Electrical Activity [PE] |
